Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
2-Ethanediamine
2-diylbis(oxy))bis(ethane-2
such as NODI and NOD2
AG-490 (50 μM) can induce apoptosis of imatinib-resistant BaF3 cells expressing T315I and E255K mutants of Bcr-Abl
Sunitinib - CAS# 557795-19-4 Size:Solid 10 mg 2-EthanediamineSunitinib free base is an oral, small molecule, multi targeted receptor tyrosine kinase (RTK) inhibitor. Sunitinib malate salt was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs). The simultaneous inhibition of these targets therefore reduces tumor
US$ 15.00
US$ 1495.00
US$ 40.00
US$ 345.00